Integration of node with primary tumor-radiomics provides the best prognostic performance in MFS prediction.<h4>Conclusion</h4>This is one of the first studies to explore the prognostic value of pre-treatment PSMA-PET, a relatively recent advancement in the care of prostate adenocarcinoma patients. Here, FOLH1 is linked to prostate adenocarcinoma.